Stephen M. Ansell, MD, PhD, discusses the investigation of loncastuximab tesirine in the phase 2 LOTIS-2 trial in relapsed/refractory diffuse large B-cell lymphoma.
Stephen M. Ansell, MD, PhD, chair, Faculty Development and Recruitment, consultant, Division of Hematology, Department of Internal Medicine, Mayo Clinic, discusses the investigation of loncastuximab tesirine (Zynlonta) in the phase 2 LOTIS-2 trial (NCT03589469) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
The LOTIS-2 trial evaluated the efficacy and safety of loncastuximab tesirine in patients with relapsed/refractory DLBCL, Ansell says, adding that the agent has shown to be a useful option forpatients who have failed previous therapies. Loncastuximab tesirine targets CD19, and it can serve as an option for patients who received agents with different targets, such as CD20, Ansell adds.
Since loncastuximab tesirine, select CAR T-cell therapies, and tafasitamab (Monjuvi) all target CD19, there have been discussions on whether challenges would arise from using the same target in different treatments, but this has not shown to be an issue thus far, Ansell explains.
Patients with relapsed/refractory DLBCL typically require multiple lines of therapy, the addition of efficacious agents to the treatment paradigm serves to benefit them, Ansell concludes.